Antibody and B‐Cell Responses to PHH‐1V81 XBB.1.16‐Adapted SARS‐CoV‐2 Booster Vaccination Are Associated With Variant Neutralization
Immune escape by SARS-CoV-2 emerging variants jeopardizes vaccine effectiveness, necessitating new immunization strategies. Here, we assessed the antibody B-cell response in 40 individuals receiving either the PHH-1V81 XBB.1.16- or BNT162b2 XBB.1.5-adapted vaccine boosters. Both immunizations significantly increased ancestral-reactive B cells cross-recognizing the vaccine variant. Notably, XBB.1.16 cross-reactive B cells were associated with neutralizing responses, reinforcing the potential of PHH-1V81 as a strong boosting candidate against emerging variants.
Authors
- Laura Ferrer
- Meritxell Deulofeu (ORCID: https://orcid.org/0000-0002-3587-6868)
- Alfons Jiménez (ORCID: https://orcid.org/0000-0003-0301-3344)
- Gemma Moncunill (ORCID: https://orcid.org/0000-0001-5105-9836)
- Luis M. Molinos‐Albert (ORCID: https://orcid.org/0000-0001-5447-6803)
- Carlota Dobaño (ORCID: https://orcid.org/0000-0002-6751-4060)
- Antoni Prenafeta
- Cèlia Torres (ORCID: https://orcid.org/0000-0002-2521-4721)
Institutions
- Universitat de Girona (ES)
- Instituto de Salud Carlos III (ES)
- Clínica Girona (ES)
- Departament de Salut (ES)
- Centro de Investigación Biomédica en Red (ES)
- Barcelona Institute for Global Health (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- Journal of Medical Virology
- Published
- 2025-08-29
- DOI
- https://doi.org/10.1002/jmv.70583
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00